AU2022270356A1 - Inhibition of eosinophilic traps - Google Patents

Inhibition of eosinophilic traps Download PDF

Info

Publication number
AU2022270356A1
AU2022270356A1 AU2022270356A AU2022270356A AU2022270356A1 AU 2022270356 A1 AU2022270356 A1 AU 2022270356A1 AU 2022270356 A AU2022270356 A AU 2022270356A AU 2022270356 A AU2022270356 A AU 2022270356A AU 2022270356 A1 AU2022270356 A1 AU 2022270356A1
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
acid sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022270356A
Other languages
English (en)
Inventor
Renato Gerardus Silvano Chirivi
Eric Charles Meldrum
Daphne MONTIZAAN
Helmuth Hendrikus Gerardus Van Es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Citryll BV
Original Assignee
Citryll BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21172160.0A external-priority patent/EP4085973A1/en
Application filed by Citryll BV filed Critical Citryll BV
Publication of AU2022270356A1 publication Critical patent/AU2022270356A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022270356A 2021-05-04 2022-05-04 Inhibition of eosinophilic traps Pending AU2022270356A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21172160.0A EP4085973A1 (en) 2021-05-04 2021-05-04 Inhibition of eosinophil extracellular traps
EP21172160.0 2021-05-04
GB2111541.5 2021-08-11
GB202111541 2021-08-11
PCT/EP2022/061970 WO2022233931A1 (en) 2021-05-04 2022-05-04 Inhibition of eosinophilic traps

Publications (1)

Publication Number Publication Date
AU2022270356A1 true AU2022270356A1 (en) 2023-09-14

Family

ID=81392799

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022270356A Pending AU2022270356A1 (en) 2021-05-04 2022-05-04 Inhibition of eosinophilic traps

Country Status (9)

Country Link
US (1) US20250084154A1 (https=)
EP (1) EP4333981A1 (https=)
JP (1) JP2024521638A (https=)
KR (1) KR20240005856A (https=)
AU (1) AU2022270356A1 (https=)
CA (1) CA3215452A1 (https=)
IL (1) IL308223A (https=)
MX (1) MX2023013021A (https=)
WO (1) WO2022233931A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
EP4442705A1 (en) 2023-04-03 2024-10-09 Citryll B.V. Dosage
GB202318703D0 (en) 2023-12-07 2024-01-24 Citryll B V Diagnostic agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
NO2294086T3 (https=) 2008-06-04 2018-02-10
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
EP2332987A1 (en) 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes
JP7037940B2 (ja) 2014-12-11 2022-03-17 シトリル べー．フェー． 特発性肺線維症の治療方法
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4

Also Published As

Publication number Publication date
IL308223A (en) 2024-01-01
MX2023013021A (es) 2024-02-12
KR20240005856A (ko) 2024-01-12
JP2024521638A (ja) 2024-06-04
US20250084154A1 (en) 2025-03-13
CA3215452A1 (en) 2022-11-10
WO2022233931A1 (en) 2022-11-10
EP4333981A1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
CN112930356B (zh) 与瓜氨酸化的组蛋白2a和/或4结合的抗体
US20250084154A1 (en) Inhibition of eosinophilic traps
CN120092020A (zh) Cnx抗原结合分子
US20190002588A1 (en) Anti-myl9 antibody
EP3682898A1 (en) Pharmaceutical composition comprising antibody binding specifically to lysyl-trna synthetase n-terminus as effective ingredient for preventing or treating immune cell migration-related disease
EP4085973A1 (en) Inhibition of eosinophil extracellular traps
CN117396221A (zh) 嗜酸性粒细胞陷阱的抑制
EA052640B1 (ru) Ингибирование внеклеточных ловушек
US12161889B2 (en) Blood brain barrier (BBB)-selective antibodies and methods of use thereof to target agents to the BBB
EP4442705A1 (en) Dosage
JP2026513830A (ja) 用量
WO2025120152A1 (en) Diagnostic agent
HK40128527A (en) Antibodies binding to citrullinated histone 2a and/or 4